LBA2 Interim efficacy analysis of REGINA, a phase II trial of neoadjuvant regorafenib (Rego), nivolumab (Nivo), and short-course radiotherapy (SCRT) in stage II-III rectal cancer (RC)

Sclafani, F.;Bregni, G.;Assaf, I.;Puleo, F.;Hendlisz, A.;et.al.
(2024) the ESMO Gastrointestinal Cancers Congress 2024 — Location: (Germany) Munich (26.June.2024)

Files

2024_Sclafani_ESMO.pdf
  • Open Access
  • Adobe PDF
  • 203.27 KB
Download

Details

Authors
  • Sclafani, F.
    Author
  • Bregni, G.
    Author
  • Assaf, I.
    Author
  • Puleo, F.
    Author
  • Van den Eynde, MarcUCLouvain
    Author
  • Hendlisz, A.
    Author
Show more
Abstract
Background : Effective strategies to tackle the immune resistance of pMMR/MSS tumors are lacking. Studies suggest a synergistic effect between immune checkpoint inhibitors, multi-kinase inhibitors and radiotherapy. We report the interim efficacy analysis of REGINA, a multicenter, single-arm, phase II trial of neoadjuvant Rego, Nivo, and SCRT for patients (pts) with stage II-III rectal adenocarcinoma (NCT04503694). [...]
Affiliations

Citations

  • APA
  • Chicago
  • FWB

Sclafani, F., Bregni, G., Assaf, I., Puleo, F., Vergauwe, P., Prenen, H., Diaz, M., Gokburun, Y., Sanchez, A. V., Anthoine, G., Moretti, L., Gomez Galdon, M., Liberale, G., Martinive, P., Geboes, K., Carrasco, J., Van den Eynde, M., van Laethem, J.-L., Buyse, M. E., & Hendlisz, A. (2024). LBA2 Interim efficacy analysis of REGINA, a phase II trial of neoadjuvant regorafenib (Rego), nivolumab (Nivo), and short-course radiotherapy (SCRT) in stage II-III rectal cancer (RC). Annals of Oncology, 35(Suppl 1), S212-S213. https://doi.org/10.1016/j.annonc.2024.06.006 (Original work published 2024)